Wells Fargo & Company MN Sells 9,987 Shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL)

Wells Fargo & Company MN lowered its stake in shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL) by 32.6% during the 4th quarter, according to its most recent filing with the SEC. The firm owned 20,619 shares of the specialty pharmaceutical company’s stock after selling 9,987 shares during the period. Wells Fargo & Company MN’s holdings in Collegium Pharmaceutical were worth $591,000 as of its most recent SEC filing.

Other institutional investors have also recently made changes to their positions in the company. New Age Alpha Advisors LLC purchased a new position in shares of Collegium Pharmaceutical during the fourth quarter valued at approximately $40,000. KBC Group NV grew its position in Collegium Pharmaceutical by 72.5% in the 4th quarter. KBC Group NV now owns 2,336 shares of the specialty pharmaceutical company’s stock worth $67,000 after purchasing an additional 982 shares during the period. Nisa Investment Advisors LLC raised its stake in Collegium Pharmaceutical by 14.5% during the 4th quarter. Nisa Investment Advisors LLC now owns 2,493 shares of the specialty pharmaceutical company’s stock valued at $71,000 after buying an additional 316 shares during the last quarter. China Universal Asset Management Co. Ltd. lifted its holdings in shares of Collegium Pharmaceutical by 10.4% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 6,838 shares of the specialty pharmaceutical company’s stock valued at $196,000 after buying an additional 642 shares during the period. Finally, Aigen Investment Management LP purchased a new position in shares of Collegium Pharmaceutical in the 4th quarter worth $230,000.

Insider Transactions at Collegium Pharmaceutical

In related news, CFO Colleen Tupper sold 977 shares of the company’s stock in a transaction on Friday, March 14th. The shares were sold at an average price of $30.00, for a total value of $29,310.00. Following the completion of the transaction, the chief financial officer now owns 164,269 shares of the company’s stock, valued at approximately $4,928,070. This represents a 0.59 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, EVP Shirley R. Kuhlmann sold 26,067 shares of the firm’s stock in a transaction dated Thursday, March 6th. The shares were sold at an average price of $28.50, for a total value of $742,909.50. Following the sale, the executive vice president now directly owns 108,137 shares in the company, valued at approximately $3,081,904.50. This represents a 19.42 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 81,693 shares of company stock valued at $2,334,994 over the last three months. Corporate insiders own 2.51% of the company’s stock.

Collegium Pharmaceutical Stock Performance

Shares of COLL opened at $27.65 on Friday. The business has a 50-day simple moving average of $28.19 and a two-hundred day simple moving average of $30.43. The company has a quick ratio of 0.88, a current ratio of 0.97 and a debt-to-equity ratio of 3.43. Collegium Pharmaceutical, Inc. has a 52 week low of $23.23 and a 52 week high of $42.29. The stock has a market cap of $888.45 million, a price-to-earnings ratio of 11.92 and a beta of 0.76.

Collegium Pharmaceutical (NASDAQ:COLL) last released its earnings results on Thursday, February 27th. The specialty pharmaceutical company reported $1.63 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.54 by $0.09. Collegium Pharmaceutical had a net margin of 14.78% and a return on equity of 104.67%. The company had revenue of $181.95 million during the quarter, compared to analyst estimates of $179.68 million. On average, analysts expect that Collegium Pharmaceutical, Inc. will post 5.62 EPS for the current year.

Analyst Ratings Changes

COLL has been the topic of a number of recent research reports. Needham & Company LLC reissued a “buy” rating and issued a $46.00 target price on shares of Collegium Pharmaceutical in a report on Wednesday, April 9th. Piper Sandler lowered their price objective on shares of Collegium Pharmaceutical from $37.00 to $36.00 and set a “neutral” rating on the stock in a research note on Tuesday, February 4th. HC Wainwright restated a “buy” rating and set a $50.00 target price on shares of Collegium Pharmaceutical in a research report on Monday, March 24th. Finally, StockNews.com downgraded shares of Collegium Pharmaceutical from a “strong-buy” rating to a “buy” rating in a research report on Saturday, April 19th. One equities research analyst has rated the stock with a hold rating and five have given a buy rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $43.60.

Collegium Pharmaceutical Profile

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.